Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar

Register now for free and join on June 10, 2026 Vancouver, Canada, June 05, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced it will host a live webinar titled "Inside MEAI: Exclusive Investigator Q&A with Yale and Johns Hopkins on Wednesday, June 10, 2026, from 12:00-1:00 PM EDT (9:00-10:00 AM PDT).